Exclusive: UK regulators give go-ahead for drug to be trialled ahead of possible treatment alongside psychotherapy
UK regulators have given the go-ahead for the first clinical trial of the use of the psychedelic drug dimethyltriptamine (DMT) to treat depression.
The trial will initially give the drug – known as the “spirit molecule” for the powerful hallucinogenic trips it induces – to healthy individuals, but it is expected to be followed by a second trial in patients with depression, where DMT will be given alongside psychotherapy.
Please follow and like us:
